TipRanks
Advertisement
Advertisement

BMRN Stock Latest News

3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
Market News3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
13h ago
BSX
BMRN
BioMarin price target lowered to $122 from $124 at Morgan Stanley
PremiumThe Fly
BioMarin price target lowered to $122 from $124 at Morgan Stanley
15h ago
BMRN
BioMarin price target raised to $87 from $86 at JPMorgan
PremiumThe Fly
BioMarin price target raised to $87 from $86 at JPMorgan
2d ago
BMRN
BioMarin assumed with a Buy at UBS
PremiumThe Fly
BioMarin assumed with a Buy at UBS
7d ago
BMRN
BioMarin price target raised to $114 from $111 at Barclays
PremiumThe Fly
BioMarin price target raised to $114 from $111 at Barclays
8d ago
BMRN
BioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR
PremiumThe FlyBioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR
13d ago
BMRN
BioMarin names Cara Bauer as Chief People Officer
Premium
The Fly
BioMarin names Cara Bauer as Chief People Officer
16d ago
BMRN
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
Premium
The Fly
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
20d ago
BMRN
BioMarin’s Palynziq Desensitization Study Signals Effort to Protect Long‑Term PKU Revenue
PremiumCompany Announcements
BioMarin’s Palynziq Desensitization Study Signals Effort to Protect Long‑Term PKU Revenue
20d ago
BMRN
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
PremiumCompany Announcements
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
21d ago
8K
BMRN
Biomarin-Linked ENERGY 2 Trial Termination: What It Means for Rare-Disease Investors
PremiumCompany Announcements
Biomarin-Linked ENERGY 2 Trial Termination: What It Means for Rare-Disease Investors
27d ago
BMRN
BioMarin price target lowered to $97 from $98 at BMO Capital
PremiumThe Fly
BioMarin price target lowered to $97 from $98 at BMO Capital
1M ago
BMRN
BioMarin ends VOXZOGO development for Noonan syndrome
PremiumCompany AnnouncementsBioMarin ends VOXZOGO development for Noonan syndrome
1M ago
8K
BMRN
BioMarin to discontinue development of Voxzogo for children with Noonan syndrome
Premium
The Fly
BioMarin to discontinue development of Voxzogo for children with Noonan syndrome
1M ago
BMRN
BioMarin Pharmaceutical Adds Independent Director to Board
Premium
Company Announcements
BioMarin Pharmaceutical Adds Independent Director to Board
1M ago
8K
BMRN
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
PremiumThe Fly
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
1M ago
BMY
BMRN
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
PremiumRatings
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
1M ago
BMRN
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
PremiumThe Fly
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
1M ago
BMRN
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
PremiumThe Fly
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
2M ago
ASND
BMRN
BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
PremiumCompany AnnouncementsBioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
2M ago
8K
BMRN
BioMarin completes agreement to acquire Alesta Therapeutics
Premium
The Fly
BioMarin completes agreement to acquire Alesta Therapeutics
2M ago
BMRN
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
Premium
Ratings
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
2M ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >